Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boden, G.
Right arrow Articles by Chen, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boden, G.
Right arrow Articles by Chen, X.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 48, Issue 3 577-583, Copyright © 1999 by American Diabetes Association

ARTICLES

Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes

G Boden and X Chen
Division of Endocrinology/Diabetes/Metabolism and the General Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.

The objective of this study was to assess the role of free fatty acids (FFAs) as insulin secretagogues in patients with type 2 diabetes. To this end, basal insulin secretion rates (ISR) in response to acute increases in plasma FFAs were evaluated in patients with type 2 diabetes and in age- and weight-matched nondiabetic control subjects during 1) intravenous infusion of lipid plus heparin (L/H), which stimulated intravascular lipolysis, and 2) the FFA rebound, which followed lowering of plasma FFAs with nicotinic acid (NA) and was a consequence of increased lipolysis from the subject's own adipose tissue. At comparable euglycemia, diabetic patients had similar ISR but higher plasma beta-hydroxybutyrate (beta-OHB) levels during L/H infusion and higher plasma FFA and beta-OHB levels during the FFA rebound than nondiabetic control subjects. Correlating ISR with plasma FFA plus beta-OHB levels showed that in response to the same changes in FFA plus beta-OHB levels, diabetic patients secreted approximately 30% less insulin than nondiabetic control subjects. In addition, twice as much insulin was secreted during L/H infusion as during the FFA rebound in response to the same FFA/beta-OHB stimulation by both diabetic patients and control subjects. Glycerol, which was present in the infused lipid (272 mmol/l) did not affect ISR. We concluded that 1) assessment of FFA effects on ISR requires consideration of effects on ISR by ketone bodies; 2) ISR responses to FFA/beta-OHB were defective in patients with type 2 diabetes (partial beta-cell lipid blindness), but this defect was compensated by elevated plasma levels of FFAs and ketone bodies; and 3) approximately two times more insulin was released per unit change in plasma FFA plus beta-OHB during L/H infusion than during the FFA rebound after NA. The reason for this remains to be explored.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
M. G. Latour, T. Alquier, E. Oseid, C. Tremblay, T. L. Jetton, J. Luo, D. C.-H. Lin, and V. Poitout
GPR40 Is Necessary but Not Sufficient for Fatty Acid Stimulation of Insulin Secretion In Vivo
Diabetes, April 1, 2007; 56(4): 1087 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J.-C. Henquin, D. Dufrane, and M. Nenquin
Nutrient Control of Insulin Secretion in Isolated Normal Human Islets
Diabetes, December 1, 2006; 55(12): 3470 - 3477.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Nigro, N. Osman, A. M. Dart, and P. J. Little
Insulin Resistance and Atherosclerosis
Endocr. Rev., May 1, 2006; 27(3): 242 - 259.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
I. Duivenvoorden, B. Teusink, P. C. N. Rensen, F. Kuipers, J. A. Romijn, L. M. Havekes, and P. J. Voshol
Acute inhibition of hepatic {beta}-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity
J. Lipid Res., May 1, 2005; 46(5): 988 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. Boden and M. Laakso
Lipids and Glucose in Type 2 Diabetes: What About the {beta}-Cell and the Mitochondria?: Response to Eldor and Raz
Diabetes Care, April 1, 2005; 28(4): 986 - 987.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
O. Wuesten, C. H. Balz, R. G. Bretzel, H.-U. Kloer, and P. D. Hardt
Effects of Oral Fat Load on Insulin Output and Glucose Tolerance in Healthy Control Subjects and Obese Patients Without Diabetes
Diabetes Care, February 1, 2005; 28(2): 360 - 365.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. A. Smith, L. E. Porter, N. Biswas, and M. I. Freed
Rosiglitazone, But Not Glyburide, Reduces Circulating Proinsulin and the Proinsulin:Insulin Ratio in Type 2 Diabetes
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6048 - 6053.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. B. Haugaard, O. Andersen, H. Storgaard, F. Dela, J. J. Holst, J. Iversen, J. O. Nielsen, and S. Madsbad
Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of {beta}-cells
Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E677 - E685.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. J. Biden, D. Robinson, D. Cordery, W. E. Hughes, and A. K. Busch
Chronic Effects of Fatty Acids on Pancreatic {beta}-Cell Function: New Insights From Functional Genomics
Diabetes, February 1, 2004; 53(90001): S159 - 165.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
J. S. Pankow, B. B. Duncan, M. I. Schmidt, C. M. Ballantyne, D. J. Couper, R. C. Hoogeveen, and S. H. Golden
Fasting Plasma Free Fatty Acids and Risk of Type 2 Diabetes: The Atherosclerosis Risk in Communities study
Diabetes Care, January 1, 2004; 27(1): 77 - 82.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Norrelund, K. S. Nair, S. Nielsen, J. Frystyk, P. Ivarsen, J. O. L. Jorgensen, J. S. Christiansen, and N. Moller
The Decisive Role of Free Fatty Acids for Protein Conservation during Fasting in Humans with and without Growth Hormone
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4371 - 4378.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. J. Pass, W. Becker, R. Kluge, K. Linnartz, L. Plum, K. Giesen, and H.-G. Joost
Effect of Hyperinsulinemia and Type 2 Diabetes-Like Hyperglycemia on Expression of Hepatic Cytochrome P450 and Glutathione S-Transferase Isoforms in a New Zealand Obese-Derived Mouse Backcross Population
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 442 - 450.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. N. Bergman, M. Ader, K. Huecking, and G. Van Citters
Accurate Assessment of {beta}-Cell Function: The Hyperbolic Correction
Diabetes, February 1, 2002; 51(90001): S212 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. J. Dyck, G. Steinberg, and A. Bonen
Insulin increases FA uptake and esterification but reduces lipid utilization in isolated contracting muscle
Am J Physiol Endocrinol Metab, September 1, 2001; 281(3): E600 - E607.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. T. Uysal, L. Scheja, S. M. Wiesbrock, S. Bonner-Weir, and G. S. Hotamisligil
Improved Glucose and Lipid Metabolism in Genetically Obese Mice Lacking aP2
Endocrinology, September 1, 2000; 141(9): 3388 - 3396.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1999 by the American Diabetes Association.